[Visualization of cerebrospinal fluid dynamics using magnetic resonance: CSF bulk flow imaging].

S. Yamada

2009-11-01

Abstract:

What problem does this paper attempt to address?

[A comparison of clinical outcomes between HLA allele matched and 1 - 2 alleles mismatched unrelated allogeneic bone marrow transplantations].

Bin Liang,He Huang,Zhen Cai,Wan-zhuo Xie,Li Li,Jing-song He,Yi Luo,Xiao-jian Meng,Wei-yan Zheng,Jie Zhang,Xiu-jin Ye,Xiao-rong Hu,Shui-yun Chen,Ai-yun Jin,Mao-fang Lin

DOI: https://doi.org/10.3760/j:issn:0253-2727.2004.02.003

2004-01-01

Abstract:OBJECTIVE:To compare the clinical outcomes between HLA allele matched (HLA-M) and 1 approximately 2 alleles disparity mismatched (HLA-mis) unrelated allogeneic bone marrow transplantation (URD-BMT). METHODS:Thirty-nine patients received HLA-M and 21 received HLA-mis URD-BMT for the treatment of acute leukemia, chronic myeloid leukemia in chronic phase (CP) and myelodysplastic syndromes (MDS) in our hospital between November 1998 and December 2002. Conditioning regimen was Bu 16 mg/kg plus CTX 120 mg/kg, and mycophenolate mofetil (MMF), CsA and MTX were given to prevent aGVHD. RESULTS:Thirty-eight of the HLA-M group and 18 of the HLA-mis group were engrafted successfully. The median follow-up duration was 11 (2.5 - 52.0) months for HLA-M group and 9 (2 - 46) months for HLA-mis group. The 3-year probabilities of disease-free survival (DFS) for HLA-M and HLA-mis group were (79.2 +/- 7.1)% and (45.8 +/- 15.5)%, respectively (P < 0.05). Grade II - IV aGVHD occurred in 10 (26.3%) patients in HLA-M group and 6 (33.3%) in HLA-mis group, respectively (P > 0.05). CONCLUSION:URD-BMT is an effective modality for the treatment of leukemia and MDS. The outcome after URD-BMT can be optimized by matching the HLA-A, B and DR alleles between the donor and recipient.
Towards Identifying the Target of Autoimmunity in Aplastic Anemia

Benjamin F Frost,Jamie Duke,Hongbo Xie,Deborah Ferriola,Joseph H Oved,Peter Nicholas,Jian-Meng Fan,Ryan Hausler,Alison A. Bertuch,Elissa M. Furutani,Akiko Shimamura,Stephanie J. Lee,Stephen R. Spellman,Dimitri S. Monos,Timothy S. Olson,Daria V. Babushok

DOI: https://doi.org/10.1182/blood-2020-136772

IF: 20.3

2020-11-05

Blood

Abstract:Acquired aplastic anemia (AA) is an autoimmune bone marrow aplasia caused by T cell-mediated destruction of hematopoietic stem and progenitor cells. The antigenic target in AA remains unknown. Recently, we and others identified frequent somatic loss of function of several human leukocyte antigen (HLA) class I alleles in hematopoietic cells that survive the AA immune attack, suggesting these alleles ("risk alleles") present autoantigen in the affected patients. We hypothesize that risk alleles share structural features and peptide-binding characteristics that may inform our understanding of the immune mechanism of AA. To identify additional AA HLA class I risk alleles, we have partnered with two multi-institutional consortia, the North American Pediatric Aplastic Anemia Consortium (NAPAAC) and the Center for International Blood and Marrow Transplant Research (CIBMTR), to evaluate 507 AA patients for somatic HLA loss. Using a combination of targeted massively parallel sequencing of HLA class I genes and single nucleotide polymorphism array genotyping, we identified HLA loss in 19% of the NAPAAC cohort (30 of 156 unselected AA patients) and 13% of the CIBMTR cohort (46 of 351 patients selected to maximize discovery of less common risk alleles). Copy number-neutral loss of heterozygosity of chromosome arm 6p (6p CN-LOH) was the most common cause of HLA loss, occurring in 50 patients (10% of total cohort, 12% NAAPAC and 9% CIBMTR). Somatic mutations were present in 45 patients (9% of total cohort, 12% of NAPAAC and 7% CIBMTR). Patients with HLA loss had a median of 1 mutant clone per patient (range 1-7). Of the somatic mutations, 80% were predicted to disrupt expression of the affected allele (through loss of start, nonsense, or frameshift mutations). The other 20% were missense mutations affecting residues in the peptide binding groove (6 mutations) and the α3 domain (9 mutations) of the HLA class I protein. A total of 19 distinct AA HLA risk alleles were identified, of which 13 were newly identified in this study. Several risk alleles (HLA-B*14:02, HLA-B*40:02, HLA-A*02:01) were enriched in AA patients compared to ethnicity matched controls. Among the 507 patients in the study, at least one risk allele was present in 436/493 (88%) of AA patients and in 34/39 (87%) of the 6p CN-LOH events. Mutations clustered in several groups of alleles (supertypes) known to bind overlapping peptide repertoires, with alleles in B27 and B44 supertypes being most commonly affected. There were no mutations in A01, A01A03, A01A24, A24, B58, B62, or in any of the HLA-C alleles analyzed. Using several metrics to estimate the strength of the autoimmune selection on a given allele, including the frequency of somatic loss and similarity to other HLA risk alleles, we developed an AA HLA risk allele pathogenicity index ranging from very high (B*14:02 and B*40:02) and high pathogenicity (A*33:03, B*08:01, B*13:02, B*14:01, B*27:03, B*27:05, B*38:02, B*41:02 and B*49:01) to those unlikely to be pathogenic. Interestingly, even within high risk supertypes such as B44, there was a wide variation in predicted pathogenicity, ranging from high (for B*40:02 and B*41:02) to low pathogenicity (for B*44:02 and B*44:03), suggesting differences in autopeptide binding. Our study provides a comprehensive analysis of AA HLA risk alleles in a large diverse cohort of AA patients. Our results suggest that HLA risk alleles have shared autoantigen binding specificities that define their pathogenicity in AA, which can be used to identify candidate AA autoantigens. HLA risk allele pathogenicity may have future clinical utility as an adjunctive diagnostic test, as well as for prognostic assessment and haploidentical donor selection. Disclosures Lee: AstraZeneca: Research Funding; Kadmon: Research Funding; Takeda: Research Funding; Novartis: Research Funding; Amgen: Research Funding; Syndax: Research Funding; Pfizer: Consultancy, Research Funding; Incyte: Consultancy, Research Funding. Monos:Omixon: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties.

hematology
Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation

Ryusuke Yamamoto,Nobuhiro Hiramoto,Ayumi Fujimoto,Hirohito Yamazaki,Takehiko Mori,Naoyuki Uchida,Noriko Doki,Jun Kato,Masashi Nishikubo,Shinichi Kako,Tetsuya Nishida,Shuichi Ota,Makoto Onizuka,Tetsuya Eto,Koichi Onodera,Kazuhiro Ikegame,Ken-ichi Matsuoka,Yoshinobu Kanda,Takahiro Fukuda,Yoshiko Atsuta,Yasushi Onishi

DOI: https://doi.org/10.1038/s41409-024-02234-1

2024-02-11

Bone Marrow Transplantation

Abstract:Posttransplant lymphoproliferative disorders (PTLD) are severe complications of allogeneic hematopoietic cell transplantation (allo-HCT), often arising from EB virus (EBV)-infected lymphocytes due to posttransplant immunosuppression. [1] Key risk factors include ex vivo or in vivo T-cell depletion, including anti-thymocyte globulin (ATG) use, and unrelated or human leukocyte antigen (HLA)-mismatched donors. [2,3,4,5,6,7,8] Other varying risk factors among studies include graft-versus-host disease (GVHD), [2,3,4,5, 9] cord blood transplantation (CBT), [2] EBV seromismatch status, [5,6,7] recipient age, [4] conditioning intensity, [5] second transplantation, [2, 4] and a history of splenectomy. [5] A retrospective study using Japanese transplant registry data identified risk factors for PTLD in various hematological diseases, including aplastic anemia (AA), ATG administration in conditioning regimens, a history of ATG treatment for acute GVHD, transplantation from donors other than HLA-matched related donors, second or subsequent transplants, and CBT. [2] A single-center study involving 89 AA patients who underwent allo-HCT from bone marrow or peripheral blood donors reported that the total number of prior courses of ATG in immunosuppressive therapy (IST) strongly influenced the high incidence of EBV-related PTLD. [10] To further evaluate the risk factors, including donor source, conditioning type, and ATG dosage, for PTLD development in adult AA patients, we conducted a nationwide multicenter retrospective analysis using Japanese transplant registry data. Patients and Methods are described in Supplementary Information. A total of 1071 patients, aged 16–75 years (median, 34 years), who underwent allo-HCT for AA were investigated. The median follow-up time for survivors was 5.2 years (range, 0.17–16.4 years). The baseline characteristics are summarized in Supplementary Table 1. Regarding the donor type, 463 patients (43%) received allo-HCT from a related donor including 54 patients (5%) from a haploidentical related donor, 432 (40%) from an unrelated donor, and 167 (16%) from cord blood (CB). Patients were classified into four groups based on their ATG usage history: patients who exclusively received ATG for IST (IST-only), patients who exclusively received ATG for conditioning regimens (Conditioning-only), patients who received ATG for both IST and conditioning regimens (Both-use), and patients who did not receive ATG (Non-use). Then, 145 (14%), 281 (26%), 261 (24%), and 374 (35%) patients were categorized into the Non-use, IST-only, Conditioning-only, and Both-use groups, respectively.

oncology,immunology,hematology,transplantation
Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation

Tingting Zhang,Yuqi Zhang,Meijia Zhou,Zhibo Zhang,Xiebing Bao,Lijun Wen,Yufeng Feng,Xiaobo Li,Mingya Zhai,Xiangjun Liu,Zhao Zeng,Xiaojin Wu,Suning Chen

DOI: https://doi.org/10.1111/bjh.19304

2024-02-09

British Journal of Haematology

Abstract:Summary To investigate the clinical characteristics and risk factors of specific human leukocyte antigen loss (HLA loss) in relapsed acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS) patients after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), and compare the responses of patients with HLA loss relapse with those without HLA loss (non‐HLA loss) to different treatment regimens. Clinical data of traceable patients with AML/MDS after myeloablative allo‐HSCT in our centre between January 2010 and June 2021, who experienced disease relapse after the transplantation, were collected. The patients were divided into the HLA loss relapse group and the non‐HLA loss relapsed group based on HLA loss gene test findings by next‐generation sequencing. The patients' median overall survival (OS) after the relapse were compared, and univariate and multivariate analyses were performed using the Kaplan–Meier survival curve and Cox proportional hazard model to explore the responses to different treatments after relapse. A total of 2359 patients were selected. Retrospective HLA gene loss gene detection was performed for the deoxyribonucleic acid in 179 relapsed patients, including 47 patients in the HLA loss group (27.2%), 126 patients in the non‐HLA loss group (72.8%) and 6 patients were excluded due to a lack of confirmed results. There was no significant statistical difference in the baseline characteristics of patients between the two groups, but as to transplantation‐related characteristics, the donor–recipient relationship and HLA mismatched loci were statistically different between the two groups (both p

hematology
Individual HLAs affect survival after allogeneic stem cell transplantation in adult T‐cell leukaemia/lymphoma

Satoko Morishima,Makoto Yoshimitsu,Takero Shindo,Atae Utsunomiya,Takashi Ishida,Ayumu Ito,Nobuaki Nakano,Toshiro Kawakita,Tetsuya Eto,Youko Suehiro,Hidehiro Itonaga,Yasuo Mori,Yasuhiko Miyazaki,Junya Kanda,Naoyuki Uchida,Yasushi Sawayama,Shouhei Tomori,Tatsuo Ichinohe,Yoshiko Atsuta,Takahiro Fukuda,Koji Kato,the ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy

DOI: https://doi.org/10.1111/tan.15555

2024-06-19

HLA

Abstract:Allogeneic haematopoietic stem cell transplantation (allo‐HSCT) is the only curative therapy for adult T‐cell leukaemia/lymphoma (ATL). Specific HLAs are associated with outcomes of immunotherapy and allo‐HSCT. We hypothesised that individual HLAs would affect the clinical outcomes of ATL patients after allo‐HSCT. Using data from a Japanese registry, we retrospectively analysed 829 patients with ATL who received transplants from HLA‐identical sibling donors or HLA‐A, ‐B, ‐C or ‐DRB1 allele‐matched unrelated donors between 1996 and 2015. We evaluated the overall mortality risk of HLA‐A, ‐B and ‐DR antigens with frequencies exceeding 3%. Outcomes were compared between transplants with or without specific HLA antigens. Of the 25 HLAs, two candidates were identified but showed no statistically significant differences by multiple comparison. HLA‐B62 was associated with a lower risk of mortality (hazard ratio [HR], 0.68; 95% confidence interval [CI]: 0.51–0.90; p = 0.008), whereas HLA‐B60 was associated with a higher risk of mortality (HR, 1.64; 95% CI: 1.19–2.27; p = 0.003). In addition, HLA‐B62 was associated with a lower risk of transplant‐related mortality (TRM) (HR, 0.52; 95% CI: 0.32–0.85, p = 0.009), whereas HLA‐B60 was associated with a higher risk of grades III–IV acute graft‐versus‐host disease (HR, 2.63; 95% CI: 1.62–4.27; p

pathology,immunology,cell biology
Risk Factors and Prognosis Analysis of Patient-Specific HLA Genomic Loss Relapse Following ATG-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation

Hengwei Wu,Ji Min Shi,Yi Luo,Jian Yu,Xiaoyu Lai,Lizhen Liu,Huarui Fu,Guifang Ouyang,Xiaojun Xu,Xiao Haowen,He Huang,Yanmin Zhao

DOI: https://doi.org/10.1182/blood-2021-147153

IF: 20.3

2021-11-05

Blood

Abstract:Abstract Background Developments in related haploidentical hematopoietic stem cell transplantation (haplo-HSCT) have made two immune systems with incompatible human leukocyte antigens (HLA) adaptable, greatly reducing transplantation-related toxicity. In the haploidentical transplantation system, patient-specific HLA antigens are a primary way in which donor immune cells exert their graft-versus-leukemia effects by alloreactivity, and therefore patient-specific HLA genomic loss is often considered a mechanism of leukemia relapse. Although the incidence and characteristics of HLA loss have been investigated in patients with myeloid leukemia who relapsed after transplantation, patient-specific HLA genomic loss in lymphoid conditions and under different transplantation regimes remain enigmatical. We herein provide the data for HLA loss relapse in lymphoid disease, as well as offer data in myeloid disease based on antithymocyte globulin (ATG) T-cell-replete conditioning. Methods Between May 2012 and May 2021, 106 patients were enrolled in this study, including 104 had hematological relapse and 2 had minimal residual disease (MRD) recurrence after haplo-HSCT. All data were collected from centers within the Zhejiang Provincial Workgroup of HSCT. Firstly, the patients were divided into two groups according to the type of disease: myeloid and lymphoid conditions, and secondly, they were divided into the Classic Group and the Loss Group according to whether the patients had unshared HLA genomic loss at the time of relapse or not. A two-tailed P value of 0.05 was considered statistically significant. Univariate analysis is performed using the χ2 test, Fisher exact test, and Student t test, as appropriate. A multivariate model was used to calculate the odds ratio (OR) with a 95% confidence interval (CI). Post relapse overall survival (prOS) was estimated and plotted using the Kaplan-Meier method. Results Of all patients, HLA loss was detected in 50.9% (54/106) patients and the occurrence was not related to disease type (P=0.44). Patients having either myeloid malignancies or lymphoid malignancies with HLA loss experienced relapse later than those with classic relapse. The demographic and baseline characteristics of patients were summarized in Table 1, and the post-relapse parameters were presented in Table 2. We next determined what factors correlating with HLA loss at relapse by multivariate analysis. For patients with myeloid malignancies, a pre-transplant underweight status based on body mass index (BMI) was a factor strongly correlated with classic type when relapse (OR=0.095, 95%CI: 0.015~0.604, P=0.013); patients suffering de novo aGVHD had an OR of 4.844 (95%CI: 1.143~20.530, P=0.032) (Figure 1). As for lymphoid conditions, patients who experiencing MRD-positivity before hematological relapse (OR=22.623, 95% CI: 1.597~320.532, P=0.021), and >180 days from HSCT to relapse (OR=5.695, 95% CI: 1.073~30.211, P=0.041) were more likely to lose unshared HLA at relapse. Yet male patients (OR=0.037, 95% CI: 0.003~0.411, P=0.037) were inclined to have classic one when relapse (Figure 1). For prognosis, in patients with myeloid conditions, the median prOS was 217 days and 215 days in the Loss Group and Classic Group, respectively (P=0.34). In the Loss Group, the white blood cell (WBC) at diagnosis was related to prOS (>50x10 9/L vs. ≤50x10 9/L: median: 157 vs. 261 days, P=0.037). For patients having male donors, patient gender was related to prOS: median prOS was 386 days for male patients and 124 days for female patients (P=0.008). For patients with lymphoid malignancies, the median prOS was 285 days and 244 days in the Loss Group and Classic Group, respectively (P=0.24). The results of the univariate analysis from the Loss Group showed that male patients (median: 40 vs. 194 days; P=0.036) and cGVHD fare (median: 114 vs. 468 days; P=0.002) were related to inferior prOS. Conclusion The occurrence of patient-specific HLA genomic relapse after haplo-HSCT appears later than classic relapse. In myeloid malignancies, the patient pre-transplant BMI and aGVHD fare are associated with the relapsed type. In lymphoid conditions, patient sex, presence of MRD-positive results before relapse, and the time from transplantation to relapse correlate with HLA loss at relapse. Yet this study is based on a limited number of patients, further validation in other centers is warranted. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

hematology
Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant

Hengwei Wu,Jimin Shi,Yi Luo,Jian Yu,Xiaoyu Lai,Lizhen Liu,Huarui Fu,Guifang Ouyang,Xiaojun Xu,Haowen Xiao,He Huang,Yanmin Zhao

DOI: https://doi.org/10.1001/jamanetworkopen.2022.6114

2022-01-01

JAMA Network Open

Abstract:IMPORTANCE Patient-specific human leukocyte antigen (HLA) genomic loss (HLA loss) is one of the reputed mechanisms of leukemia immune escape and relapse after haploidentical hematopoietic stem cell transplant (HSCT). However, clinical characteristics and prognosis of this distinct relapse type in the setting of haploidentical HSCT based on antithymocyte globulin (ATG) T-cell-replete conditioning are still unknown, especially for patients with lymphoid leukemia. OBJECTIVE To identify the incidence of and patient characteristics associated with HLA loss at hematologic cancer relapse after ATG-based haploidentical HSCT and to assess overall survival after HLA loss at relapse. DESIGN, SETTING, AND PARTICIPANTS This retrospective and multicenter case series study used data from medical records to identify patients who experienced relapse of hematologic cancer after receipt of ATG-based haploidentical HSCT. The study included 788 consecutive patients aged 8 to 70 years with lymphoid or myeloid leukemia who received ATG T-cell-replete haploidentical HSCT at the Zhejiang Cooperative Group for Blood and Marrow Transplantation between May 1, 2012, and May 31, 2021. EXPOSURES Relapse after ATG-based haploidentical HSCT. MAIN OUTCOMES AND MEASURES Incidence, risk factors, and postrelapse overall survival among patients with HLA loss at hematologic cancer relapse after receipt of haploidentical HSCT. Logistic regression analysis was used to identify characteristics associated with the likelihood of HLA loss, and Kaplan-Meier and Cox regression analyses were performed to evaluate postrelapse survival. RESULTS A total of 788 patients who received haploidentical HSCT for hematologic cancer were identified, 180 of whom experienced relapse after HSCT. Of those, 106 evaluable patients (median age, 30.9 years [range, 8.3-64.6 years]; 54 female [50.9%] and 52 male [49.1%]) were screened for HLA loss, which was detected in 54 patients (50.9%). Patients with NIA loss experienced relapse later than those without HLA loss (lymphoid group: median, 323 days [range, 98-2056 days] vs 151 days [range, 57-2544 days]; P = .01; myeloid group: median, 321 days [range, 55-1574 days] vs 223 days [range, 68-546 days]; P = .03). Among patients with lymphoid leukemia, those with minimal residual disease positivity before hematologic relapse (odds ratio [OR], 28.47; 95% CI, 1.99-407.98; P = .01), those with chronic graft-vs-host disease (OR, 27.68; 95% CI, 1.40-546.88; P = .03), and those with more than 180 days between HSCT and relapse (OR, 6.91; 95% CI, 1.32-36.22; P = .02) were more likely to lose unshared HLA at relapse, whereas male patients (OR, 0.03; 95% CI. 0.003-0.32; P = .04) were more likely to preserve their HLA genome at relapse. Patients with myeloid leukemia had different factors associated with HLA loss, including underweight status (OR, 0.10; 95% CI, 0.02-0.60; P = .01) and acute graft-vs-host disease (OR, 4.84; 95% CI, 1.14-20.53; P = .03). The receipt of preemptive donor lymphocyte infusion among patients with minimal residual disease recurrence did not postpone hematologic cancer relapse in those with HLA loss (median, 322 days [range, 204-1030 days]) compared with no receipt of donor lymphocyte infusion (median, 340 days [range, 215 days to not available]; P > .99). CONCLUSIONS AND RELEVANCE In this study, HLA loss at leukemia relapse occurred frequently after receipt of ATG-based haploidentical HSCT. The identification of risk factors associated with HLA loss would help to prompt screening, avoid potentially harmful infusions of donor T cells, and develop alternative therapeutic strategies.
Impact of ABO Incompatibility on Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

Yan-Ru Ma,Wen-Jing Wang,Yi-Fei Cheng,Yuan-Yuan Zhang,Xiao-Dong Mo,Ting-Ting Han,Feng-Rong Wang,Chen-Hua Yan,Yu-Qian Sun,Yu-Hong Chen,Jing-Zhi Wang,Fei-Fei Tang,Wei Han,Yu Wang,Xiao-Hui Zhang,Xiao-Jun Huang,Lan-Ping Xu

DOI: https://doi.org/10.1038/s41409-020-0779-7

2020-01-01

Bone Marrow Transplantation

Abstract:The impact of ABO incompatibility on transplantation outcomes in severe aplastic anemia (SAA) patients receiving haploidentical hematopoietic stem cell transplantation (HSCT) remains controversial without published data. A total of 199 SAA patients receiving haploidentical HSCT from ABO-matched (n = 114), minor ABO-incompatible (n = 47), or major ABO-incompatible donors (n = 38) were included in this study. The median time and cumulative incidences of both myeloid and platelet engraftment in the ABO-compatible and ABO-incompatible groups were similar, and pure red cell aplasia was absent. Minor ABO incompatibility increased the rate of grade III–IV acute graft-versus-host disease (aGVHD) (ABO compatible: 6.14 ± 0.05%, minor incompatible: 19.15 ± 0.34%, and major incompatible: 10.53 ± 0.25%; P = 0.051), but did not influence the rates of grade II–IV aGVHD or chronic GVHD (cGVHD). Minor ABO-incompatibility was identified as an independent risk factor for grade III–IV aGVHD by multivariate analysis (hazard ration (HR) = 4.00 (1.48–10.80), P = 0.006). Chronic GVHD, mortality, and treatment failure were not increased in the minor ABO-incompatible group. For SAA patients receiving haploidentical HSCT, ABO compatible donors are better than ABO minor incompatible donors if several haploidentical donors are available.
Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia

Yuanfeng Zhang,Jiali Huo,Li Liu,Yuyan Shen,Juan Chen,Tingting Zhang,Xin Chen,Aiming Pang,Donglin Yang,Rongli Zhang,Qiaoling Ma,Weihua Zhai,Yi He,Jialin Wei,Erlie Jiang,Mingzhe Han,Yizhou Zheng,Sizhou Feng

DOI: https://doi.org/10.3389/fimmu.2022.837335

IF: 7.3

2022-02-01

Frontiers in Immunology

Abstract:We retrospectively compared the outcomes of 387 consecutive patients with acquired aplastic anemia (AA) who underwent hematopoietic stem cell transplantation (HSCT) with a fludarabine-based conditioning regimen from matched sibling donors (MSD) (n = 108) or haploidentical donors (HID) (n = 91) and immunosuppressive therapy (IST) (n = 188) from 2014 to 2020 at our hospital. Compared with HID-HSCT, MSD-HSCT had a lower incidence of graft failure (1% vs. 7%, p = 0.062), grade II–IV acute graft versus host disease (aGvHD) (16% vs. 35%, p = 0.001), and mild to severe chronic GvHD (cGvHD) (8% vs. 23%, p = 0.007), but an equivalent incidence of grade III–IV aGvHD (8% vs. 12%, p = 0.237) and moderate to severe cGvHD (3% vs. 9%, p = 0.076). HSCT had superior blood count recovery at 3, 6, and 12 months compared with IST ( p < 0.001). The estimated 5-year overall survival (OS) of the MSD, HID, and IST groups were 86%, 72%, and 79% ( p = 0.02), respectively; accordingly, the failure-free survival (FFS) rates were 85%, 68%, and 56%, respectively ( p < 0.001). For patients aged ≤40 years, the OS rate was still significantly superior for MSD-HSCT receipients compared to HID-HSCT receipients (89% vs. 76%, p = 0.024) while the HID-HSCT recipients showed similar OS (76% vs. 78%, p = 0.166) but superior FFS ( p = 0.047) when follow-up was longer than 14.5 months in contrast to IST. In a multivariate analysis, HID-HSCT and a conditioning regimen that included busulfan were adversely related to OS among patients who received allografts. In conclusion, MSD-HSCT was the frontline choice for patients with severe AA aged ≤40 years, while HID-HSCT was as effective as IST for patients without an MSD.

immunology
The PDZ domain of OutC and the N-terminal region of OutD determine the secretion specificity of the type II out pathway of Erwinia chrysanthemi.

Julien Bouley,G. Condemine,V. Shevchik

DOI: https://doi.org/10.1006/JMBI.2001.4594

IF: 6.151

2001-04-27

Journal of Molecular Biology

Abstract:The plant pathogens Erwinia chrysanthemi and Erwinia carotovora secrete multiple exoproteins by a type II pathway, the Out system. Secretion in Erwinia is species-specific: exoproteins of one species cannot be secreted by the other. We analysed the role of two components of the Out system, the bitopic inner membrane protein OutC and the secretin OutD, in the specific recognition of secreted proteins. We demonstrated that the PDZ domain of OutC determines its secretion specificity towards certain exoproteins. The secretin is the major determinant of specificity of the Out system: OutD of E. carotovora changes the secretion specificity of E. chrysanthemi and enables it to secrete heterologous exoproteins. Construction of chimeric OutD showed that the N-terminal region is the specificity domain of the secretin. Thus, both the PDZ domain of OutC and the N-terminal region of OutD are required for specific recognition of secreted proteins. Systematic analysis of the secretion of several exoproteins demonstrated that different exoproteins secreted by the Out machinery have different requirement for their presumed targeting signals on OutC and OutD. This strongly indicates that diverse exoproteins possess a variable number of targeting signals which are recognised by different regions of OutC and OutD.
HLA‐lacking clones in aplastic anaemia: Adaptive or maladaptive?

Carmelo Gurnari,Alberto Cardoso Martins Lima,Simona Pagliuca

DOI: https://doi.org/10.1111/bjh.19731

2024-08-28

British Journal of Haematology

Abstract:HLA loss represents the result of immune forces shaping bone marrow clonal dynamics in immune aplastic anaemia. Human leukocyte antigen (HLA)‐deficient clones may rescue haematopoiesis by evading immune attacks, potentially guiding treatment strategies. Commentary on: Zaimoku et al. Haematopoietic regeneration by HLA‐A*0206‐deficient clones in severe aplastic anaemia without definitive immunosuppressive treatment. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19712.

hematology
Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.

W. A. van Deijk,G. Blijham,W. Mellink,P. Meulenberg

Abstract:Postmenopausal patients with metastatic breast cancer were treated with aminoglutethimide (AG) and high-dose medroxyprogesterone acetate (MPA). Studying the interaction between the two drugs as far as plasma MPA and cortisol levels are concerned we observed a 50% decrease of plasma MPA levels after the addition of AG (P less than 0.005). With large interindividual differences in plasma MPA levels, a significant correlation with serum cortisol levels was found (P less than 0.001). It can be concluded that AG leads to a lowering of plasma MPA levels to such an extent that its adrenal suppressive effect may be diminished or even abrogated. In future trials of MPA with or without AG correlations between plasma MPA levels, serum cortisol levels and treatment response should be taken into account.
Comparable Clinical Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hepatitis-Associated Aplastic Anemia and Non-Hepatitis-associated Aplastic Anemia.

Ma, Xiaodi,Zuo, Yangyang,Xu, Zhengli,Zhang, Yuanyuan,Cheng, Yifei,Han, Tingting,Suo, Pan,Sun, Yuqian,Tang, Feifei,Wang, Fengrong,Yan, Chenhua,Chen, Yuhong,Wang, Yu,Zhang, Xiaohui,Liu, Kaiyan,Huang, Xiaojun,Xu, Lanping

DOI: https://doi.org/10.1007/s00277-022-04885-w

2022-01-01

Annals of Hematology

Abstract:Hepatitis-associated aplastic anemia (HAAA), a rare subtype of aplastic anemia (AA), is defined as bone marrow failure occurring after acute hepatitis. Severe HAAA requires immunosuppressive therapy (IST) or hematopoietic stem cell transplantation (HSCT) as lifesaving treatment. The outcomes of HAAA patients who underwent haploidentical hematopoietic stem cell transplantation (haplo-HSCT) have not been systematically evaluated. We retrospectively compared the characteristics of 15 patients with HAAA and 60 non-hepatitis-associated aplastic anemia (non-HAAA) patients, all 75 of whom underwent haplo-HSCT in our hospital between January 2006 and October 2021. The median ages of the patients were 18 years old (range, 3–36) for HAAA patients and 13 years (range, 2–45) for non-HAAA patients (p = 0.693). The median time for neutrophil engraftment was 14 days (range, 11–22) in the HAAA group and 12 days (range, 10–21) in the non-HAAA group (p = 0.363). At the time of analysis, 15 HAAA patients and 58 non-HAAA patients were alive, and their median follow-up times were 37 (range, 3–87) months and 31 (range, 2–110) months (p = 0.347), respectively. There were no significant differences in the three-year overall survival (OS) rates (100% vs. 96.7 ± 0.33%, P = 0.638) or liver event-free survival (LEFS) (80.0 ± 0.17% vs. 76.7 ± 0.19%, P = 0.747) between the two groups. Despite the small number of HAAA patients due to the rarity of the disease, these results, such as the similar incidence rates of 3-year OS and fewer liver events than expected, suggest that haplo-HSCT is a feasible treatment for HAAA a when there are no human leukocyte antigen (HLA)-matched donors available and has a low risk of transplant-related mortality and complications.
Haematopoietic regeneration by HLA‐A*0206‐deficient clones in severe aplastic anaemia without definitive immunosuppressive treatment

Yoshitaka Zaimoku,Kazuya Sakai,Noriaki Tsuji,Kazuyoshi Hosomichi,Shinya Yamada,Dung Cao Tran,Miku Kobayashi,Ayana Sugiyama,Kouyuki Hirayasu,Hiroki Mizumaki,Ken Ishiyama,Rikinari Hanayama,Yoshiaki Tomiyama,Shinji Nakao

DOI: https://doi.org/10.1111/bjh.19712

2024-08-19

British Journal of Haematology

Abstract:Summary We describe the case of a 74‐year‐old man with severe aplastic anaemia who experienced persistent remission attributed to proliferation of HLA allele‐deficient clones. Despite an initial worsening of pancytopenia with eltrombopag and ciclosporin treatment, gradual trilineage haematopoietic recovery occurred, with blood counts normalizing over 3 years. Flow cytometry and deep nucleotide sequencing revealed that haematopoiesis was primarily supported by several clones with somatic mutations that inactivated antigen presentation via HLA‐A*0206. This suggests that monitoring haematopoietic regeneration by immune escape clones could be an alternative approach for immune aplastic anaemia patients who possess HLA allele‐deficient clones and cannot tolerate standard therapy.

hematology
ABO Mismatching and Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia—a Report from the ALWP of the EBMT

Bipin N. Savani,Myriam Labopin,Jonathan Canaani,Xiao-Jun Huang,William Arcese,Johanna Tischer,Yener Koc,Benedetto Bruno,Zafer Gulbas,Didier Blaise,Johan A. Maertens,Gerhard Ehninger,Frederic Baron,Norbert Gorin,Jordi Esteve,Christoph Schmid,Sebastian Giebel,Fabio Ciceri,Mohamad Mohty,Arnon Nagler

DOI: https://doi.org/10.1016/j.bbmt.2017.01.015

2017-01-01

Biology of Blood and Marrow Transplantation

Abstract:Background: About 30-50% of HLA-matched hematopoietic stem cell transplantation (HCT) are performed with ABOmismatch (ABO-MM) donor, which can be classified as either major, minor or bidirectional. The impact of ABO-MM on clinical outcome after HCT remains controversial and no large series is available to study the impact of ABO-MM in patients (pts) receiving haploidentical-HCT (haplo-HCT). Methods: 837 pts with AML that underwent haplo-HCT from January 2005 to December 2014 were analyzed to study the long term impact of ABO-mismatching in haplo-HCT. The comparative analysis was performed between pts receiving ABO-matched vs. ABO-MM for common outcome variables. Results: 522 (62%) pts received ABO-matched whereas 315 (38%) underwentABO-MMhaplo-HCT including 150 (18%) minor ABOMM (minor-A, 75 [50%]), 127 (15%) major ABO-MM (major-O, 98 [77%]) and 38 (5%) bidirectional ABO-MM (Bidirectional-A, 20 [53%]). Median agewas 42 years (range, 18-77) andwas not significantly different between ABO groups (P = .67). The median follow-up period was 36 months (IQR, 23-53). Median year of transplantationwas 2011. More than half of ptswere in CR1 and nearly one third of pts were with active disease prior to transplantation. 497 (59%) pts received ablative and 340 (41%) reduced intensity or non-ablative conditioning regimen. 219 (26%) of pts received BM, 240 (29%)BM+PB, 378 (45%) PB alone and 123 (15%) ex-vivo T-cell depleted grafts. There were no significant differences in distributions of pts and transplant characteristics among ABO- groups. 771 (94%) pts engrafted and the percentage of engraftmentwas lower in the major mismatch group (88% vs 95% in other group, P = .007). The cumulative incidences (CI) of day 100 grade II-IV acute GVHDwas 31% (III-IV, 10%) and the 3-year CI of chronic GVHD was 31% (95% CI, 27-34), and were not significantly different between the ABO-groups (P = .124 and .392). There was no differences in OS, RI, and NRM between ABOgroups. Bidirectional ABO-group had improved 3-year LFS (67%) and GFRS (54%) compared to other ABO-group in univariate analysis. Therewas no impact of ABO-MM when T-cells replete and T-depleted groups analyzed separately. In multivariate analysis, our data showed no significant differences in OS, LFS, RI, NRM, and chronic GVHD between ABO-groups. The analyses were performed separately for pts receiving PB and BM+/-PB grafts. There was no statistical difference between ABO-groups for OS, LFS, RI, NRM, GFRS and chronic GVHD in pts receiving PB grafts. However, among BM group, pts with minor ABO-MM recipients had significantly higher acute GVHD (HR 2; 95% CI, 1-4; P = .048) without impacting other transplant outcome. Conclusion: Despite the limitation of a retrospective registry based study, our large series shows no significant long term outcome difference between ABO matched and mismatched groups after haplo-HCT in current era.
Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience

QingYun Wang,HanYun Ren,ZeYin Liang,Wei Liu,Yue Yin,QingYa Wang,Qian Wang,YuHua Sun,WeiLin Xu,ZhiXiang Qiu,JinPing Ou,Na Han,Jing Wang,YuJun Dong,Yuan Li

DOI: https://doi.org/10.3389/fmed.2021.807527

IF: 3.9

2022-01-01

Frontiers in Medicine

Abstract:Clinical data of patients with severe aplastic anemia (SAA) were retrospectively analyzed to evaluate the outcomes of haploidentical hematopoietic stem cell transplantation (HID-HSCT) with matched related sibling hematopoietic stem cell transplantation (MSD-HSCT) in complications and survivals. Thirty consecutive patients were enrolled in the study with a median follow-up of 50 months (range 4, 141), and the median age of the patients was 21 years (range 3, 49). All the patients achieved myeloid engraftment in the two cohorts. The cumulative incidences of platelet engraftment were 95.5 and 100% in HID cohort and MSD cohort, respectively. The median time for neutrophil and platelet recovery was 11 (range 9, 19) and 15 (range 10, 25) days in HID cohort, and 12 (range 10, 19) and 14 (range 8, 25) days in MSD cohort. The cumulative incidences of grade II-IV and grade III-IV acute graft vs. host disease (aGvHD) in HID cohort and in MSD cohort were 18.9 vs. 14.3% (p = 0.77) and 10.5 vs. 0% (p = 0.42), respectively. The cumulative incidences of chronic graft vs. host disease (cGvHD) was 22.7% in HID cohort and 25.5% in MSD cohort (p = 0.868). The 5-year overall survival (OS) rates and 5-year failure-free survival (FFS) rates in HID cohort and MSD cohort were 85.1 vs. 87.5% (p = 0.858), 80.3 vs. 87.5% (p = 0.635), respectively. The median time to achieve engraftment, cumulative incidence of aGvHD and cGvHD, and the 5-year OS and FFS rates were not significantly different between the two cohorts. We suggest that HID-HSCT might be a safety and effective option for SAA patients without a matched donor.
The obligation of ophthalmic organizations to report their actions.

F. Newell

DOI: https://doi.org/10.1016/S0002-9394(14)73989-3

1992-08-01

Abstract:
[Haploidentical hematopoietic stem cell transplantation in the treatment of acquired aplastic anemia in children: a single center retrospective analysis]

R M Luo,X M Zhang,Z L Du,Y Wang,W Chen,W J Gu,Y J Si,G S Xing,B Hu,W M Da

DOI: https://doi.org/10.3760/cma.j.issn.0578-1310.2018.07.011

2018-07-02

Abstract:Objective: To investigate the safety and efficacy of haploidentical hematopoietic stem cell transplantation with different intensity conditioning regimen in the treatment of childhood aplastic anemia (AA) . Methods: Thirty-seven AA patients who underwent haploidentical transplantation in BaYi Children's Hospital Affiliated to PLA Army General Hospital from January 2013 to January 2017 were enrolled. According to the dosage of conditioning regimen, 34 patients excluding 3 other conditioning regimens were divided into high-dosage group (regimen 2, 22 cases) and low-dosage group (regimen 3, 12 cases). The data of Engraftment, graft-vs-host disease (GVHD), hematopoietic reconstitution, relapse, infection, overall survival (OS) were analyzed. The comparison between the two groups was tested by χ(2) test. Results: A total of 35 of 37 patients achieved primary engraftment; 2 cases died of regimen-related toxicity and severe infection before the infusing of the grafts. The activation rate of CMV and EBV was 60% (21/35) . Post-transplant lymphocyte disease (PTLD) of lung occurred in one case. The cumulative incidences of acute GVHD grade Ⅰ-Ⅳ and chronic GVHD were 29% (10/35) and 34% (12/35) respectively and the incidence of extensive chronic GVHD was 6% (2/35) . The median follow-up time was 18.8 (2.9-44.1) months, the OS was 92% (34/37) .All survived patients were no longer dependent on blood transfusion and none of them had recurrence. Comparing the rates of overall survival(86%(19/22) vs.100%(12/12)) and rates of chronic GVHD(40%(8/20) vs. 17%(2/12)) in regimen 2 and regimen 3 group, there were no significant difference (χ(2)=1.742, 1.841, all P>0.05) . Significant difference was found at the incidence of Ⅰ-Ⅳ acute GVHD (10% (2/20) vs. 50% (6/12) ,χ(2)=6.200, P=0.013). Conclusions: Haploidentical hematopoietic stem cell transplantation is effective and safe. It is suitable for patients who are not eligible for matched donor transplantation. Application of reduced dose preconditioning in haploid transplantation is worth exploring.
Outcome of Haploidentical Hematopoietic Stem Cell Transplantation for Refractory/relapsed Acute Leukemia

Yu Wang,Dai-hong Liu,Kai-yan Liu,Lan-ping Xu,Xiao-hui Zhang,Wei Han,Huan Chen,Yu-hong Chen,Feng-rong Wang,Jing-zhi Wang,Hai-xia Fu,Xiao-jun Huang

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2012.11.007

2012-01-01

Abstract:Objective To explore the outcome of human leukocyte antigen (HLA)-mismatched/haploidentical hematopoietic stem cell transplantation (HSCT) for refractory/relapsed acute leukemia (AL) patients and its related risk factors.Methods 96 refractory/relapsed AL patients who received HLA-mismatched/haploidentical HSCT following conditioning regimen comprised of modified busulfan/cyclophosphamide (BU/CY) plus thymoglobulin (ATG) from Jan 2003 to Jun 2011 were analyzed retrospectively.Results Of the 96 patients,61 suffered from acute myeloid leukemia(AML),and 35 acute lymphoid leukemia (ALL),all of them in non-remission (NR) or relapse before transplantation.With a median follow-up of 373 (34-3157) d,33 cases(34％) survived,31 survived without leukemia,and 35 relapsed.The estimated 3-year overall survival (OS) and disease-free survival (DFS) rate was 30.2％ and 29.0％,respectively.The 3-year OS rate was significantly higher for AML patients (39.2％) than for ALL patients (15.4％) (P =0.005).The estimated 3-year OS probabilities for patients with and without prophylactic donor lymphocyte infusion (DLI) were 38.0％ and 11.8％,respectively (P =0.001).Sex,age,conditioning regimen (BU/CYor not,dosage of ATG),the number of HLA mismatches between the donor and recipient,and the number of infused mononuclear cells were not independent factors affecting OS,DFS and relapse.Multivariate analysis showed that DFS rate was significantly higher in patients receiving prophylactic DLI(P =0.003),in patients with AML(vs with ALL) (P=0.037) and with chronic GVHD(P =0.006).Conclusions Haploidentical HSCT may prolong DFS in part refractory/relapsed AL patients and even cure them.Prophylactic DLI may reduce relapse and increase survival ; for patients with refractory/relapsed ALL,other therapy for prevention and treatment of post-transplant relapse should be explored.
A Novel Protocol for Haploidentical Hematopoietic SCT Without in Vitro T-cell Depletion in the Treatment of Severe Acquired Aplastic Anemia

L P Xu,K Y Liu,D H Liu,W Han,H Chen,Y H Chen,X H Zhang,Y Wang,F R Wang,J Z Wang,X J Huang

DOI: https://doi.org/10.1038/bmt.2012.79

2012-01-01

Biology of Blood and Marrow Transplantation

Abstract:Mismatched related donors of hematopoietic SCT (HSCT) for severe aplastic anemia (SAA) present challenges mainly associated with graft failure and GVHD. The greater the HLA disparity, the poorer the OS. About 19 consecutive SAA/very SAA (VSAA) patients who received HSCT from haploidentical family donors in our center are reported in this study, 18/19 pairs had 2–3 loci mismatched. All 19 cases failed to respond to previous therapy and were heavily transfused before transplantation. The conditioning regimen before HSCT included BU, CY and thymoglobulin. The recipients received CsA, mycophenolate mofetil (MMF) and short-term MTX for GVHD prophylaxis. The source of stem cell grafts was a combination of G-CSF-primed BM and G-CSF-mobilized peripheral blood stem cells. All patients achieved 100% donor myeloid engraftment; the median time for myeloid engraftment was 12 days (ranging from 10–29 days) and for platelets was 18 days (ranging from 8–180 days) with a cumulative platelet engraftment incidence of 84.21±10.53%. The cumulative incidence was 42.1±11.3% for grade II–IV acute GVHD and 56.2±12.4% for chronic GVHD. The OS was 64.6±12.4% with a median 746-day (90–1970) follow-up for surviving patients. These limited retrospective analysis data suggest that HLA-haploidentical HSCT for SAA patients without an HLA-identical sibling donor might be feasible. Further research to increase OS by decreasing GVHD while maintaining stable engraftment will be needed in the future.

[Visualization of cerebrospinal fluid dynamics using magnetic resonance: CSF bulk flow imaging].

[A comparison of clinical outcomes between HLA allele matched and 1 - 2 alleles mismatched unrelated allogeneic bone marrow transplantations].

Towards Identifying the Target of Autoimmunity in Aplastic Anemia

Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation

Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation

Individual HLAs affect survival after allogeneic stem cell transplantation in adult T‐cell leukaemia/lymphoma

Risk Factors and Prognosis Analysis of Patient-Specific HLA Genomic Loss Relapse Following ATG-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation

Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant

Impact of ABO Incompatibility on Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia

The PDZ domain of OutC and the N-terminal region of OutD determine the secretion specificity of the type II out pathway of Erwinia chrysanthemi.

HLA‐lacking clones in aplastic anaemia: Adaptive or maladaptive?

Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.

Comparable Clinical Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hepatitis-Associated Aplastic Anemia and Non-Hepatitis-associated Aplastic Anemia.

Haematopoietic regeneration by HLA‐A*0206‐deficient clones in severe aplastic anaemia without definitive immunosuppressive treatment

ABO Mismatching and Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia—a Report from the ALWP of the EBMT

Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience

The obligation of ophthalmic organizations to report their actions.

[Haploidentical hematopoietic stem cell transplantation in the treatment of acquired aplastic anemia in children: a single center retrospective analysis]

Outcome of Haploidentical Hematopoietic Stem Cell Transplantation for Refractory/relapsed Acute Leukemia

A Novel Protocol for Haploidentical Hematopoietic SCT Without in Vitro T-cell Depletion in the Treatment of Severe Acquired Aplastic Anemia